EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123	NDA	Gilead Sciences, Inc.	61958-1101-1	30 TABLET, FILM COATED in 1 BOTTLE (61958-1101-1)	2011-08-10
Mylan	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	208452	ANDA	Mylan Pharmaceuticals Inc.	0378-5440-93	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-5440-93)	2025-05-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

The demand for antiretroviral drugs, such as emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate, continues to rise globally due to the ongoing HIV/AIDS epidemic. The complexity of manufacturing these compounds and their critical role in combination therapies necessitates a reliable, high-quality supply chain. This article provides an in-depth overview of the primary suppliers of these drugs, focusing on their manufacturing capacity, market influence, and strategic positioning within the global pharmaceutical supply chain.

Overview of the Drugs

Emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI), is fundamental in HIV regimen formulations. It is often combined with other antiretrovirals, including tenofovir disoproxil fumarate (TDF) and rilpivirine, to enhance efficacy.

Rilpivirine hydrochloride serves as a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used predominantly in second-line HIV therapies. Its stability and bioavailability have made it a preferred choice in fixed-dose combination (FDC) products.

Tenofovir disoproxil fumarate (TDF) is another NRTI, a cornerstone in antiretroviral therapy (ART), both as a component of single-tablet regimens and in combination with other agents.

Their manufacturing is concentrated within a select group of pharmaceutical giants and specialized chemical producers, given the complexity, regulatory standards, and patent considerations involved.

Key Suppliers for Emtricitabine

1. Gilead Sciences

Gilead Sciences is the original patent holder for emtricitabine, marketed under the brand name Emtriva. They maintain extensive manufacturing capabilities and supply agreements globally, particularly in high-income markets where patent protection persists.

Manufacturing footprint: Gilead operates multiple manufacturing facilities in the US and Ireland, with collaborations with third-party producers to meet global demand.
Market presence: Dominant provider in the premium segment, with a significant share in North America and Europe.
Patent and licensing status: Patent exclusivity limits generic production in many jurisdictions, though patent expirations in some regions have led to increased generic activity.

2. Hetero Labs

Hetero Laboratories (India) is among the leading generic API producers. Their capacity to produce high-quality emtricitabine has made them a key supplier in developing markets.

Production capacity: Hetero's cGMP-certified facilities can produce large volumes, with a robust export footprint.
Market: Supplies to multiple generic drug manufacturers aiming for affordable ART regimens.
Regulatory approvals: Their products are often aligned with WHO prequalification standards.

3. Sun Pharmaceutical Industries

Sun Pharma is another major Indian API manufacturer, supplying emtricitabine API and finished formulations to developing nations.

Manufacturing capabilities: Extensive API manufacturing unit, with a focus on quality and cost-competitiveness.
Global reach: Supplies both as raw API to generics firms and directly as finished formulations.

Suppliers for Rilpivirine Hydrochloride

1. Janssen Pharmaceuticals (Johnson & Johnson)

Janssen developed rilpivirine as part of their HIV portfolio, marketing it under the brand Edurant.

Manufacturing infrastructure: Facilities in Belgium and the US produce rilpivirine hydrochloride API.
Market dominance: As patent holder, Janssen retains primary supply authority for branded formulations.
Generic competition: Limited until patent expiry; however, they partner with generic manufacturers in specific regions to ensure market stability post-patent.

2. Cipla Limited

Cipla, an Indian pharmaceutical giant, produces rilpivirine API for generic formulations, especially aimed at emerging markets.

Manufacturing: State-of-the-art facilities capable of GMP-standard API production.
Market scope: Supplies to multiple generic and biosimilar companies globally.
Certification and approval: Their products are WHO-GMP approved, facilitating global acceptance.

3. Dr. Reddy's Laboratories

Dr. Reddy’s manufactures rilpivirine API, focusing heavily on expanding affordable HIV treatment options.

Global footprint: Supplies API for generic formulations across Asia, Africa, and Latin America.
Capacity: Continually expanding production capacity to meet global demand.

Suppliers for Tenofovir Disoproxil Fumarate

1. Gilead Sciences

As the patent owner, Gilead remains a primary supplier for TDF globally, with long-standing manufacturing capacity.

Manufacturing locations: Multiple facilities including in the US and Ireland.
Market share: Dominates first-line HIV therapy markets and hepatitis B treatment.
Strategic partnerships: Engages with Indian generics for licensed production in specific territories.

2. Hetero Labs

Hetero’s production of tenofovir disoproxil fumarate API complements Gilead’s offerings, filling gaps in developing markets.

Production capacity: Large-scale manufacturing conforming to international standards.
Certification: WHO-GMP, USFDA approvals facilitate global distribution.

3. Mylan (now part of Viatris)

Mylan, a prominent generic pharmaceutical producer, is engaged in manufacturing TDF API, with an emphasis on high-volume, low-cost supply to emerging markets.

Global reach: Supplies API and finished drugs across Africa, Asia, and Latin America.
Regulatory approvals: Focuses on countries with environmental and pharmacovigilance standards.

Emerging and Regional Suppliers

In recent years, biosimilar and generic manufacturers in India and China have scaled up production of these antiretroviral drugs, driven by domestic demand and international licensing agreements:

Cipla, Natco Pharma, and Aurobindo Pharma (India): Active players offering affordable generics, often under licensing agreements.
Shanghai Miracuz Pharmaceutical (China): Growing presence in API production, supported by rapid capacity expansion.
Others: Small to medium-sized firms in Latin America and Southeast Asia are increasingly entering the market, often through technology transfer agreements with established producers.

Regulatory and Supply Chain Considerations

The supply landscape for these antiretrovirals is complex, shaped by patent protections, licensing agreements, and international procurement standards such as WHO prequalification and Stringent Regulatory Authority (SRA) approvals (e.g., USFDA, EMA). Manufacturers with global certifications tend to dominate supply chains, especially for branded and high-income country markets.

Manufacturers are also increasingly investing in quality assurance, capacity expansion, and technology transfer to emerging markets in response to the demand for affordable generics. The potential for supply disruptions—whether due to geopolitical factors, raw material shortages, or pandemic-related disruptions—remains a key concern for procurement agencies.

Conclusion

The global supply chain for emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate hinges on a handful of major multinational and regional players. Gilead Sciences maintains dominant control over patent-protected formulations, while Indian generics—such as Hetero, Cipla, and Dr. Reddy's—are vital for accessible, affordable generics, especially in developing countries. Ongoing capacity expansion and licensing arrangements are crucial to meet global HIV treatment goals.

Key Takeaways

Dominant Manufacturers: Gilead Sciences leads in patent-protected formulations, while Indian generics companies are essential for large-scale, cost-effective production.
Strategic Agreements: Licensing and technology transfer agreements shape supply chains, especially in emerging markets.
Regulatory Standards: WHO prequalification and stringent regulatory approvals are critical for market access and supply reliability.
Market Trends: Patent expiries and biosimilar development are poised to diversify the supplier landscape further.
Supply Chain Resilience: Diversification, capacity expansion, and quality assurance are vital to mitigate risks associated with supply disruptions.

FAQs

1. Who are the main patent holders for emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate?
Gilead Sciences is the patent holder of emtricitabine and tenofovir disoproxil fumarate, while Janssen Pharmaceuticals holds the patent for rilpivirine hydrochloride.

2. Which regions rely heavily on generic suppliers for these drugs?
Developing regions such as Africa, South Asia, and parts of Latin America significantly depend on Indian and Chinese pharmaceutical companies for affordable generics.

3. How do licensing agreements influence the supply of these drugs?
Licenses granted by patent holders enable generic manufacturers to produce and distribute these drugs legally, expanding access while maintaining patent protections in certain markets.

4. What certifications are vital for suppliers to export these drugs globally?
WHO prequalification, USFDA approval, and EMA certifications ensure compliance with international standards and facilitate access to global procurement programs.

5. Are there new suppliers or alternative sources emerging for these drugs?
Yes, ongoing capacity expansion and technological advances in China and India are increasing the number of capable suppliers, promising greater supply resilience in the future.

References

Gilead Sciences. (2023). Emtricitabine and Tenofovir Disoproxil Fumarate Supply Details.
Janssen Pharmaceuticals. (2023). Rilpivirine Market and Manufacturing Information.
WHO Prequalification Programme. (2022). List of Approved Antiretroviral APIs and Finished Products.
Indian Pharmaceutical Alliance. (2021). Market Analysis of Generics in HIV Treatment.
U.S. Food & Drug Administration. (2023). Approved Drug Listings for Antiretrovirals.

Suppliers and packagers for generic pharmaceutical drug: EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE